Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 5/20 | 0.32 |
| ▸ | CA1 | P00915 | 5/20 | 0.32 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | CA9 | Q16790 | 5/20 | 0.32 |
| ▸ | CA7 | P43166 | 3/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288698 | 0.85 | TSHR (0.53) | TSHRHCAR2ALDH1A1CA12CA1 | |
| SCHEMBL8437495 | 0.83 | TSHR (0.60) | TSHRHCAR2ALDH1A1CA12CA1 | |
| SCHEMBL3706557 | 0.81 | TSHR (0.57) | TSHRHCAR2ALDH1A1CA12CA1 | |
| SCHEMBL6471616 | 0.79 | TSHR (0.48) | TSHRHCAR2ALDH1A1CA12CA1 | |
| SCHEMBL36670 | 0.78 | TSHR (0.59) | TSHRHCAR2ALDH1A1CA12CA1 | |
| Propane SCHEMBL22462424 | 0.78 | TSHR (0.46) | TSHRHCAR2ALDH1A1CA12CA1 | |
| SCHEMBL5490374 | 0.78 | TSHR (0.46) | TSHRHCAR2ALDH1A1CA12CA1 | |
| SCHEMBL4785172 | 0.77 | TSHR (0.46) | TSHRHCAR2ALDH1A1LMNACHRM2 | |
| SCHEMBL4582656 | 0.77 | — | — | |
| SCHEMBL28340544 | 0.76 | TSHR (0.43) | TSHRHCAR2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | ARBOR PHARMACEUTICALS, LLC | 2021-07-29 | — | — | US | claimed |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-11-27 | — | — | US | claimed |
| US-20140057917-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| US-10945984-B2 | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3027767-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XenoPort, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9006225-B2 | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| WO-2015017762-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XENOPORT, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140057917-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2236135-A1 | STABLE PHARMACEUTICAL COMPOSITION | Asahi Kasei Pharma Corporation (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-0008917-B1 | PENAM-3-CARBOXYLIC ACID 1,1-DIOXIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | PFIZER INC. (US) | 1982-11-24 | — | — | EP | disclosed |
| US-4241050-A | Penam 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1980-12-23 | — | — | US | disclosed |
| EP-0008917-A1 | Penam-3-carboxylic acid 1,1-dioxides, process for their preparation and pharmaceutical compositions | PFIZER INC. (US) | 1980-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057917-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | TSHR 4532/4885HCAR2 1463/4885ALDH1A1 626/4885 |
| US-10945984-B2 | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects | FH, FAH, ALDOA | TSHR 4532/4885HCAR2 1463/4885ALDH1A1 626/4885 |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | TSHR 4532/4885HCAR2 1463/4885ALDH1A1 626/4885 |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | TSHR 536/4885HCAR2 51/4885ALDH1A1 996/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | TSHR 4029/4885HCAR2 74/4885ALDH1A1 409/4885 |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | TSHR 4532/4885HCAR2 1463/4885ALDH1A1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.